Results 151 to 160 of about 6,658 (202)
Limited Clinical Benefit of Immune Checkpoint Inhibition in Ovarian Cancer with Opportunities in Selected Subtypes. [PDF]
Int J Mol SciRatka Z, Gamian A, Woźniak M.
europepmc +1 more source
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer [PDF]
New England Journal of Medicine, 2023 In a phase 2 study, rucaparib, an inhibitor of poly(ADP-ribose) polymerase (PARP), showed a high level of activity in patients who had metastatic, castration-resistant prostate cancer associated with a deleterious BRCA alteration. Data are needed to confirm and expand on the findings of the phase 2 study.In this randomized, controlled, phase 3 trial ...
Simon Watkins +2 more
exaly +7 more sources
Imaging PARP With [18F]Rucaparib in Pancreatic Cancer Models [PDF]
European Journal of Nuclear Medicine and Molecular Imaging, 2022 PURPOSE: Rucaparib, an FDA-approved PARP inhibitor, is used as a single agent in maintenance therapy to provide promising treatment efficacy with an acceptable safety profile in various types of BRCA-mutated cancers. However, not all patients receive the
Bart Cornelissen +2 more
exaly +2 more sources
A Phase II Trial of Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium
Gynecologic Oncology, 2022 Objective: The aim of this study was to examine the tolerability and efficacy of combination bevacizumab rucaparib therapy in patients with recurrent cervical or endometrial cancer.
Kai Ding, L L Holman, R S Mannel
exaly +2 more sources
Clinical and Molecular Characteristics of ARIEL3 Patients Who Derived Exceptional Benefit From Rucaparib Maintenance Treatment for High-Grade Ovarian Carcinoma [PDF]
Gynecologic Oncology, 2022 OBJECTIVE: ARIEL3 (NCT01968213) is a placebo-controlled randomized trial of the poly(ADP-ribose) polymerase inhibitor rucaparib as maintenance treatment in patients with recurrent high-grade ovarian carcinoma who responded to their latest line of ...
Margarita Amenedo Gancedo +2 more
exaly +2 more sources
A Phase I Study of Intravenous and Oral Rucaparib in Combination With Chemotherapy in Patients With Advanced Solid Tumours [PDF]
British Journal of Cancer, 2017 Background: This study evaluated safety, pharmacokinetics, and clinical activity of intravenous and oral rucaparib, a poly(ADP-ribose) polymerase inhibitor, combined with chemotherapy in patients with advanced solid tumours. Methods: Initially,
Richard H Wilson +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Rucaparib for the treatment of ovarian cancer
Expert Opinion on Orphan Drugs, 2017ABSTRACTIntroduction: Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors (PARPi) are evolving as one of the most promising therapies in ovarian cancers, especially for patients with a BRCA1/2 or Homologous Recombination Repair (HRR) defect. Rucaparib is one of the three PARPi approved for use in ovarian cancer. Recent research has opened an
Sunu Lazar Cyriac +2 more
openaire +1 more source
Rucaparib: A Review in Ovarian Cancer
Targeted Oncology, 2019Rucaparib (Rubraca®) is a small molecule poly(ADP-ribose) polymerase (PARP) inhibitor with potent activity against PARP-1, -2 and -3. It is approved in the USA and the EU for the treatment of adult patients with BRCA-mutated ovarian cancer who have been treated with two or more lines of chemotherapy. Rucaparib is also approved in the USA and the EU for
openaire +2 more sources
Rucaparib: First Global Approval
Drugs, 2017Rucaparib (Rubraca™) is an oral, small molecule, poly (ADP-ribose) polymerase inhibitor being developed by Clovis Oncology, Inc. (Boulder, CO, USA) for the treatment of solid tumours. It has been approved in the USA as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer ...
openaire +2 more sources
Rucaparib: a new treatment option for ovarian cancer
Expert Opinion on Pharmacotherapy, 2018Approximately 50% of high-grade serous ovarian cancers present a deficiency in the pathways involved in homologous recombination (HR). PARP inhibitors prevent single-strand DNA damage repair and determine a progression of the defect towards double-strand breaks, which results in a process known as 'synthetic lethality'.
Ilaria, Sabatucci +5 more
openaire +2 more sources